Feb. 14 at 2:01 PM
$CRDL Geographic Enrollment Dynamics for MAVERIC
European sites have only recently begun enrolling, but management reports strong
interest across the region driven by a distinct treatment dynamic. In many
European centers, the predominant IL-1 inhibitor is anakinra (Kineret), which
requires daily injections rather than weekly dosing. Although effective, anakinra is
costly, associated with relapse upon withdrawal, and the daily injection burden
represents a meaningful limitation for patients. In addition, corticosteroids are used
more sparingly in Europe, further increasing unmet need once patients fail first-line
therapy. As a result, investigators and clinicians have expressed strong
enthusiasm for a treatment that could reduce reliance on chronic daily injections
while avoiding prolonged immune suppression.
While U.S. enrollment is currently leading, as expected, management views
Europe as an important secondary enrollment and long-term growth driver, continue to ramp.
